Alizyme investors eye payout

Investors in collapsed biotech firm Alizyme may receive a small payout after administrator Grant Thornton sold its weight-loss and diabetes drug Cetilistat. Privately owned drugs developer Norgine paid £4.6m for the drug, though the deal has still got to be cleared by the regulators. It is not known how much money would be passed to creditors.